Furthermore, even after tapering mepolizumab to 200 mg every 4 weeks, her condition remained stable without relapse of EGPA and without increases in the eosinophil count and MPO-ANCA titer. The gene discussed is MPO; the disease is eosinophilic granulomatosis with polyangiitis.